| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Studies |
Department of Medicine (C.K., H.U.H., S.M.), University of Tübingen, D 72076 Tübingen, Germany; the Department of Medicine, University of Heidelberg (A.H.), Heidelberg, Germany; the Departments of Medicine (P.A.) and Pathology (A.N.), University of Hamburg, Hamburg, Germany; the Diabetes Research Institute, University of Dusseldorf (I.U., J.E.), Düsseldorf, Germany; the Department of Medicine, University of Cologne (D.M.W.), Cologne, Germany; the Department of Pharmacology, University of Aachen (H.G.J.), Aachen, Germany; the Department of Diabetes and Metabolism, Krankenhaus Bethanien (M.D.), Hamburg, Germany; and the Department of Medicine, University of Vienna (H.W.R.), Vienna, Austria
Address all correspondence and requests for reprints to: Stephan Matthaei, M.D., Department of Medicine IV, Endocrinology, Metabolism, and Pathobiochemistry, University of Tübingen, Otfried Müller Strasse 10, D 72076 Tübingen, Germany. E-mail: snmattha{at}med.uni-tuebingen.de
The purpose of this study was to examine the molecular mechanism responsible for the defective insulin-stimulated glucose transport in cultured fibroblasts from a patient (VH) with clinical features of Werner syndrome and severe insulin resistance. Thus, in cells derived from VH, the subcellular distribution, structure, functional activity, as well as plasma membrane insertion of GLUT1 glucose transporters were analyzed. Furthermore, the insulin signal transduction pathway leading to activation of phosphatidylinositol (PI) 3-kinase as well as components of GLUT1-containing membrane vesicles were characterized.
In fibroblasts derived from VH, GLUT1 glucose transporters were
overexpressed by 8-fold in plasma membranes (PM) and by 5-fold in high
density microsomes, respectively. Exofacial photolabeling revealed that
only 14% of the overexpressed PM-GLUT1 transporters were properly
inserted into the plasma membrane. The complementary DNA structure of
the patients insulin receptor and the GLUT1 glucose transporter, the
intrinsic activity of plasma membrane glucose transporters, the
tyrosine phosphorylation, as well as the protein expression of insulin
receptor substrate-1/2 and p85
/ß- and p110
/ß-subunits of PI
3-kinase were normal. However, insulin-stimulated association of the
p85 subunit of PI 3-kinase was defective in fibroblasts derived from VH
compared to those from controls, and this defect was associated with a
reduced IRS-1-dependent activation of PI 3-kinase by 50.2% and 63.6%
after incubation for 5 and 10 min with 100 nmol/L insulin,
respectively. Furthermore, immunodetection of small GTP-binding Rab
proteins in subcellular membrane fractions indicated a decreased
expression of Rab4 in total cellular homogenates as well as in high
density microsomes by 70% and 58%, respectively. After preparation of
GLUT1-containing vesicles, Rab4 was not detected to be a component of
these vesicles. Analysis of the PI 3-kinase in GLUT1-containing
membrane vesicles revealed insulin-dependent targeting of the p85
subunit to the vesicles immunoadsorbed from VH and control fibroblasts.
Importantly, the association of the p85 subunit as well as the
p85-immunoprecipitable PI 3-kinase activity were markedly reduced in
GLUT1-vesicles derived from the patient.
In conclusion, impaired PI 3-kinase activity in GLUT1-containing membrane vesicles derived from fibroblasts of VH is associated with a defective docking and/or fusion process of glucose transporters with the plasma membrane and thus might contribute to the molecular defect causing insulin resistance in this patient.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |